| Identification | Back Directory | [Name]
NSC781406 | [CAS]
1676893-24-5 | [Synonyms]
NSC781406
NSC-781406;NSC 781406
NSC781406;NSC-781406;NSC 781406
Benzenesulfonamide, 2,4-difluoro-N-[2-methoxy-5-[4-[3-[4-(methylsulfonyl)-1-piperazinyl]-1-propyn-1-yl]-6-quinolinyl]-3-pyridinyl]- | [Molecular Formula]
C29H27F2N5O5S2 | [MOL File]
1676893-24-5.mol | [Molecular Weight]
627.68 |
| Chemical Properties | Back Directory | [Boiling point ]
775.1±70.0 °C(Predicted) | [density ]
1.52±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10mg/mL; DMSO: 20mg/mL; DMSO:PBS (pH 7.2) (1:4): 0.2mg/mL | [form ]
A solid | [pka]
6.23±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
NSC 781406 is a dual inhibitor of PI3K and mammalian target of rapamycin (mTOR; IC50s = 2.0, 9.4, 2.7, 14, and 5.4 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR, respectively). It inhibits cell growth in the NCI-60 panel of cancer cell lines (mean GI50 = 65 nM). NSC 781406 (30 mg/kg) reduces tumor volume in a BEL-7404 hepatic cancer mouse xenograft model. | [Uses]
NSC781406 is a highly potent PI3K and mTOR inhibitor with an IC50 of 2 nM for PI3Kα. | [in vivo]
In the xenograft models, treatment with 30 mg/kg of NSC781406 results in statistically significant antitumor activity, with a mean reduction in relative tumor volume ratio of 52%. Sorafenib displays an inhibition ratio of 44% at 50 mg/kg. NSC781406 is well tolerated at 30 mg/kg, with no observed mortality or significant reduction of body weight[1]. | [IC 50]
PI3Kα: 2 nM (IC50); PI3Kγ: 2.7 nM (IC50); PI3Kβ: 9.4 nM (IC50); PI3Kδ: 14 nM (IC50); mTOR: 5.4 nM (IC50) | [References]
[1] Chen Y, et al. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma. Bioorg Med Chem. 2016 Mar 1;24(5):957-66. DOI:10.1016/j.bmc.2016.01.008 |
|
|